Olema Pharmaceuticals, Inc. (OLMA)
Largest Insider Buys in Sector
OLMA Stock Price History Chart
OLMA Stock Performance
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema …
Insider Activity of Olema Pharmaceuticals, Inc.
Over the last 12 months, insiders at Olema Pharmaceuticals, Inc. have bought $3.03M and sold $57.23M worth of Olema Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Olema Pharmaceuticals, Inc. have bought $26.67M and sold $16.57M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Graham G. Walmsley (director) — $5.61M. Paradigm Biocapital Advisors LP (10 percent owner) — $1.16M.
The last purchase of 100,000 shares for transaction amount of $1.16M was made by Paradigm Biocapital Advisors LP (10 percent owner) on 2023‑12‑06.
List of Insider Buy and Sell Transactions, Olema Pharmaceuticals, Inc.
| 2024-08-01 | Sale | 10 percent owner | 2.4M 3.888% | $14.91 | $35.8M | -27.40% | ||
| 2024-07-30 | Sale | director | 934 0.0017% | $15.55 | $14,524 | +5.85% | ||
| 2024-07-29 | Sale | director | 4,066 0.0075% | $15.58 | $63,348 | -21.17% | ||
| 2024-07-11 | Sale | director | 5,000 0.0099% | $12.26 | $61,300 | 0.00% | ||
| 2024-06-28 | Sale | director | 20,000 0.0348% | $10.77 | $215,400 | 0.00% | ||
| 2024-06-04 | Sale | director | 5,000 0.0079% | $12.33 | $61,650 | -12.73% | ||
| 2024-06-04 | Sale | director | 1.18M 2.2298% | $14.85 | $17.45M | -12.73% | ||
| 2024-06-03 | Sale | director | 5,000 0.0083% | $10.93 | $54,650 | +3.65% | ||
| 2024-05-31 | Sale | director | 15,000 0.0261% | $9.41 | $141,150 | +25.90% | ||
| 2024-05-06 | Sale | director | 5,000 0.009% | $10.92 | $54,600 | +9.00% | ||
| 2024-04-30 | Sale | director | 15,000 0.0251% | $9.51 | $142,650 | +16.62% | ||
| 2024-03-28 | Sale | director | 20,000 0.0347% | $10.97 | $219,400 | +2.92% | ||
| 2024-02-29 | Sale | director | 25,000 0.0455% | $12.41 | $310,309 | -6.21% | ||
| 2024-02-01 | Sale | director | 5,000 0.0118% | $15.56 | $77,800 | -22.36% | ||
| 2024-01-31 | Sale | director | 25,000 0.0463% | $12.23 | $305,750 | -9.13% | ||
| 2023-12-29 | Sale | director | 25,000 0.0434% | $13.38 | $334,500 | -16.09% | ||
| 2023-12-06 | 10 percent owner | 100,000 0.1816% | $11.60 | $1.16M | +0.64% | |||
| 2023-12-05 | director | 131,870 0.2639% | $14.19 | $1.87M | -8.46% | |||
| 2023-11-30 | Sale | director | 25,000 0.0412% | $12.57 | $314,250 | -15.29% | ||
| 2023-11-22 | Sale | director | 3,989 0.0074% | $13.90 | $55,447 | -13.60% |
Insider Historical Profitability
| Paradigm Biocapital Advisors LP | 10 percent owner | 783118 1.3668% | $8.10 | 1 | 1 | |
| Graham G. Walmsley | director | 700761 1.223% | $8.10 | 3 | 1 | <0.0001% |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 424987 0.7417% | $8.10 | 2 | 2 | +244.38% |
| BVF PARTNERS L P/IL | 4688954 8.1835% | $8.10 | 3 | 0 | <0.0001% | |
| Cormorant Asset Management, LP | 3270544 5.708% | $8.10 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $103.42M | 16.33 | 9.14M | 0% | +$0 | 0.76 | |
| Paradigm BioCapital Advisors LP | $89.47M | 14.13 | 7.9M | 0% | +$0 | 3.25 | |
| Logos Global Management Lp | $49.63M | 7.84 | 4.38M | 0% | +$0 | 5.36 | |
| Deep Track Capital Lp | $36.51M | 5.77 | 3.23M | +67.04% | +$14.65M | 0.17 | |
| BlackRock | $36.41M | 5.75 | 3.22M | -1.45% | -$536,035.96 | <0.01 |